АкушерствоАнатомияАнестезиологияВакцинопрофилактикаВалеологияВетеринарияГигиенаЗаболеванияИммунологияКардиологияНеврологияНефрологияОнкологияОториноларингологияОфтальмологияПаразитологияПедиатрияПервая помощьПсихиатрияПульмонологияРеанимацияРевматологияСтоматологияТерапияТоксикологияТравматологияУрологияФармакологияФармацевтикаФизиотерапияФтизиатрияХирургияЭндокринологияЭпидемиология

ЗАКЛЮЧЕНИЕ. За последние 10 лет произошли существенные изменения в понимании патогенетических процессов, лежащих как в основе эмфиземы

За последние 10 лет произошли существенные изменения в понимании патогенетических процессов, лежащих как в основе эмфиземы, так и в разработке новых подходов к ведению больных. Внедрение новых методов лучевой диагностики позволяет устанавливать диагноз эмфиземы уже на ранних стадиях болезни до появления клинических проявлений. Современные лечебные технологии дают возможность уменьшить симптомы заболевания, улучшить качество и продолжительность жизни пациентов с эмфиземой легких.

СПИСОК ЛИТЕРАТУРЫ

1.National Heart Lung and Blood Institute. The definition of emphysema. Report of a Division of Lung Diseases workshop.// Am Rev Respir Dis 1985;132:182 - 185.

2.Mason RJ, Murray JF, Broaddus VC, Nadel JA. Textbook of Respiratory Medicine.// Fourth Edition, Elsevier inc., USA 2005, Vol 1. P 1117.

3.Hayashi S, Hogg JC. Adenovirus infections and lung disease //Curr Opin Pharmacol. 2007 Apr 17

4.Theegarten D, Mogilevski G, Anhem O, et al. The role of Chlamydia in the pathogenesis of pulmonary emphysema// Virchows Arch 2000;437:190 - 3

5.Martinez FJ, Curtis JL, Sciurba F. Gender Differences in Severe Pulmonary Emphysema// Am J Respir Crit Care Med. 2007 Apr 12;

6. Изаксон Э. О патолого-анатомических изменениях легочных сосудов при эмфизематозном процессе в легких.// Пульмонология, 2005 4б С.41-52

7.Voelkel N. F., Vandivier R. W, Tuder R. M.Vascular endothelial growth factor in the lung //Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L209 - L221

8.Santos S, Peinado VI, Ramirez J et al. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease.//Am J Respir Crit Care Med (2003) 167: 1250-1256

9.Kranenburg A Rl. Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease // Thorax 2005;60:106-113

10.Tudern RM, Zhen L, Cho CY. Oxidative Stress and Apoptosis Interact and Cause Emphysema Due to Vascular Endothelial Growth Factor Receptor Blockade.// Am J of Respir Cell and Molec Biol. 2003.Vol. 29, pp. 88-97

11.Harris WH, Chillingworth FP. The experimental production in dogs of emphysema with associated asthmatic syndrome by means of an intratracheal ball valve.// J Exp Med 1919;30:75 - 85.

12.Laurell CB, Erickson S. The electrophoretic a1-globulin pattern of serum in a1-antitrypsin deficiency.// Scan J Clin Lab Invest 1963;15:132 - 140

13.Gross P, Babjak M, Tolker E, et al. Enzymatically produced pulmonary emphysema: A preliminary report.//J Occup Med 1964; 6:481-484

14.Mercer R., Crapo J. D. Structural changes in elastic fibers after pancreatic elastase administration in hamsters. //J. Appl. Physiol. 1992; 72: 1473-1479

15.Orsos F.: Au Uber das elastische Gerauust der normalen und der emphysematosen Lunge.// Pathol. Anat. 41: 95-121, 1907.

16.Hogg JC, Senior RM Chronic obstructive pulmonary disease: Pathology and biochemistry of emphysema// Thorax 2002;57:830-834

17.American Thoracic Society. Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency.// Am. J. Respir. Crit Care Med. 2003;168: 818-900

18.The Alpha 1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha 1-antitrypsin. Am. J. Respir Criti Care Med. 1998; 158:49-59

19. Carp H., Miller F., Hoidal J.R., Janoff A. Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity.// Proc. Natl. Acad. Sci. USA. 1982; 79: 2041 - 2045.

20.Taggart C., Cervantes-Laurean D., Kim G. Oxidation of either Methionine 351 or Methionine 358 in 1-Antitrypsin Causes Loss of Anti-neutrophil Elastase Activity. J. Biol. Chem. 2000; 275 (35): 27258-27265.

21.Finlay, GA, O’Driscoll, LR, Russell, KJ, et al: Matrix metalloproteinase expression and production by alveolar macrophages in emphysema.// Am. J. Respir. Crit. Care Med., Volume 156, Number 1, July 1997, 240-247

22.Vernooy J, Lindeman J H, Jacobs JA: Increased Activity of Matrix Metalloproteinase-8 and Matrix Metalloproteinase-9 in Induced Sputum From Patients With COPD// Chest. 2004;126:1802-1810

23.Imai K, Dalal S, Chen E Human Collagenase (Matrix Metalloproteinase-1) Expression in the Lungs of Patients with Emphysema// Am. J. Respir. Crit. Care Med., Volume 163, Number 3, March 2001, 786-791

24.Selman M, Cisneros-Lira J, Gaxiola M et al: Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in guinea pigs// Chest (2003) 123: 1633-1641.

25.Beeh KM, Beier J, Kornmann O, Buhl R Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1 and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects.// Respir Med 97(2003): 634-639

26.Higashimoto Y, Yamagata Y Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients// Eur Respir J. 2005 May;25(5):885-90.

27. Vignola A, Riccobono M, Mirabella A. Sputum Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 Ratio Correlates with Airflow Obstruction in Asthma and Chronic Bronchitis //Am. J. Respir. Crit. Care Med., Volume 158, Number 6, December 1998, 1945-1950

28.Joyce E. Rundhaug Matrix metalloproteinases and angiogenesis// J. Cell. Mol. Med. Vol 9, No 2, 2005 pp. 267-285

29.Russell RE, Thorley A, Culpitt SV et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases// Am J Physiol Lung Cell Mol Physiol 2002;283:867 - 873.

30. Takeyabu K, Betsuyaku T, Nishimura M et al. Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema// Eur Respir J 1998;12:1033 - 1039

31.Wang Z, Zheng T, Zhu Z et al. Interferon gamma induction of pulmonary emphysema in the adult murine lung// J Exp Med 2000;192:1587 - 1600

32.Henson P.M., Vandivier RW, Douglas S.I. Cell Death, Remodeling, and Repair in Chronic Obstructive Pulmonary Disease?// The Proceedings of the American Thoracic Society (2006)3:713-717

33.Fang KC, Wolters PJ, Steinhoff M, et al. Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-beta.// J Immunol 1999;162:5528 - 35

34.Kucich U, Rosenbloom JC, Abrams WR, et al.: Transforming growth factor-beta stabilizes elastin mRNA by a pathway requiring active Smads, protein kinase C-delta and p38.// Am J Respir Cell Mol Biol 2002;26:183 - 8

35.Bonniaud P, Kolb M, Galt T et al: Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis.//J Immunol 2004;173:2099 - 2108

36.Pons R, Sauleda J., Noguera A. et al: Decreased macrophage release of TGF-бета and TIMP-1 in chronic obstructive pulmonary disease // Eur. Respir. J., July 1, 2005; 26(1): 60 - 66

37.Aoshiba K, Nagai A. Differences in airway remodeling between asthma and chronic obstructive pulmonary disease.//Clin Rev Allergy Immunol 2004;27:35 - 43

38.Hodge S, Hodge G, Scicchitano R et al. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells.// Immunol Cell Biol. 2003;81:289 - 296.

39.Vandivier RW, Fadok VA, Hoffmann PR et al: Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis.// J Clin Invest. 2002;109:661 - 670

40.Vlanovich G, Russel ML, Mercer RR, Crapo JD. Cellular and Connective Tissue Changes in Alveolar Septal Walls in Emphysema //Am. J. Respir. Crit. Care Med., Vol 160, Number 6, 1999, 2086-2092

41.Massaro GD, Radaeva S, Clerch LB, Massaro D. Lung alveoli: endogenous programmed destruction and regeneration// Am J Physiol Lung Cell Mol Physiol 2002.283: 305-309

42.Barnes P. J., Stockley R. A. COPD: current therapeutic interventions and future approaches //Eur Respir J 2005; 25:1084-1106

43.Stein J, Fenigstein H. Pathological anatomy of hunger disease.// In: Winick M, editor. Hunger disease: studies by the Jewish physicians in the Warsaw Ghetto: current concepts in nutrition. New York: John Wiley & Sons; 1979. p. 207 - 211

44.Kerr JS, Riley DJ, Lanza-Jacoby S, et al. Nutritional emphysema in the rat // Am Rev Respir Dis 1985;131:644 - 650

45.Coxson H., Ida H. Chan T., Mayo J Early Emphysema in Patients with Anorexia Nervosa// Am J Respir and Crit Care Med 2004;Vol 170. pp. 748-752

46.Patel BD, Loo WJ, Tasker AD et al. Smoking related COPD and facial wrinkling: is there a common susceptibility? Thorax. 2006 Jul;61(7):568-671

47.Uppaluri R, Mitsa T, Sonka M et al. Quantification of pulmonary emphysema from lung computed tomography images.// Am J Respir Crit Care Med 1997;156:248 - 254

48.Sanders C, Nath PH, Bailey W. Detection of emphysema with computed tomography: correlation with pulmonary function tests and chest radiography.// Invest Radiol 1988;23:262 - 266

49.Власов П.В. Лучевая диагностика заболеваний органов грудной полости// «Видар», 2006, стр.65-77

50.Morgan MDL: Detection and quantification of pulmonary emphysema by computed tomography: a window of opportunity// Thorax 1992;47:1001 - 1004

51.Gevenois PA, de Maertelaer V, De Vuyst P et al.: Comparison of computed density and macroscopic morphometry in pulmonary emphysema.// Am J Respir Crit Care Med 1995;152:653 - 657

52.Parr D. G., Dawkins P. A., Stockley R. A. Computed tomography: a new gold standard for the clinical assessment of emphysema//Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 954 - 954

53.Watz H, Breithecker A, Rau W. Micro-CT of the Human Lung: Imaging of Alveoli and Virtual Endoscopy of an Alveolar Duct in a Normal Lung and in a Lung with Centrilobular Emphysema - Initial Observations// Radiology 2005;236:1053-1058

54.Chapman K.R., Stockley R.A., Dawkins C. et al. Augmentation therapy for альфа1-antitrypsin deficiency: a meta-analysis of randomized and non-randomized clinical studies.// Eur. Respir. J. 2005; 26 (49): 288

55.Wencker M., Fuhrmann B., Banik N. et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.// Chest. 2001; 119:737-744.

56.Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.// Chest 2000; 118:1480 - 1485.

57.Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial.// Am J Med 2000;109:207 - 212.

58.Finnerty JP, Keeping I, Bullough I, Jones J: The effectiveness of outpatient pulmonary rehabilitation in chronic lung disease: randomized controlled trial// Chest 2001; 119: 1705-1710

59.Martinez F, Foster G, Curtis J. Predictors of Mortality in Patients with Emphysema and Severe Airflow Obstruction// American Journal of Respiratory and Critical Care Medicine Vol 173. pp. 1326-1334, (2006)

60.Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.// N Engl J Med 2004; 350:1005 - 1012

61.Kanner RE, Renzetti AD, Stanish WM et al. Predictors of survival in subjects with chronic airflow limitation// Am J Med 1983;74:249 - 255.

62.Nikoladze G.D. Functional results of surgery for bullous emphysema.// Chest 101: 119-122, 1992

63.Brantigan O, Mueller E. Surgical treatment of pulmonary emphysema.// Am Surg 1957. 23,789-804.

64.Cooper, JD, Trulock, EP, Triantafillou, AN, et al. Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease.// J Thorac Cardiovasc Surg (1995) 109,106-116.

65.Meyers BF, Yusen RD, Guthrie TJ, et al: Results of lung volume reduction surgery in patients meeting a national emphysema treatment trial high-risk criterion. //J Thorac Cardiovasc Surg 2004. 127:829-835

66.Tutic M, Lardinois D, Imfeld S.: Lung-Volume Reduction Surgery as an Alternative or Bridging Procedure to Lung Transplantation.// Ann Thorac Surg 2006; 82:208-213.

67.Wan IY, Toma TP, Geddes DM. Bronchoscopic Lung Volume Reduction for End-Stage Emphysema Report on the First 98 Patients// Chest. 2006;129:518-526

68.Meyers BF, Patterson GA Chronic obstructive pulmonary disease. 10: Bullectomy, lung volume reduction surgery, and transplantation for patients with chronic obstructive pulmonary disease// Thorax. 2003 Jul;58(7):634-8

document:

$pr:

version: 01-2007.1

codepage: windows-1251

type: klinrek

id: kli3121071

: 08.3. БРОНХИАЛЬНАЯ АСТМА

meta:

author:

fio[ru]: А.В. Емельянов, Б.А. Черняк, Н.П. Княжеская, М.О. Потапова, А.С. Белевский

codes:

next:

type: dklinrek

code: III.III

type: dkli00023

Дата добавления: 2015-01-18 | Просмотры: 1108 | Нарушение авторских прав